Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc. 2024-02-13 03:26
1